Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5M32

Human 26S proteasome in complex with Oprozomib

Summary for 5M32
Entry DOI10.2210/pdb5m32/pdb
EMDB information4146
DescriptorProteasome subunit alpha type-2, Proteasome subunit beta type-2, Proteasome subunit beta type-5, ... (35 entities in total)
Functional Keywordsproteasome, oprozomib, ups, drug-binding, hydrolase
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains47
Total formula weight1535198.08
Authors
Haselbach, D.,Schrader, J.,Lambrecht, F.,Henneberg, F.,Chari, A.,Stark, H. (deposition date: 2016-10-14, release date: 2017-07-05, Last modification date: 2025-04-09)
Primary citationHaselbach, D.,Schrader, J.,Lambrecht, F.,Henneberg, F.,Chari, A.,Stark, H.
Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs.
Nat Commun, 8:15578-15578, 2017
Cited by
PubMed Abstract: The proteasome holoenzyme is the major non-lysosomal protease; its proteolytic activity is essential for cellular homeostasis. Thus, it is an attractive target for the development of chemotherapeutics. While the structural basis of core particle (CP) inhibitors is largely understood, their structural impact on the proteasome holoenzyme remains entirely elusive. Here, we determined the structure of the 26S proteasome with and without the inhibitor Oprozomib. Drug binding modifies the energy landscape of conformational motion in the proteasome regulatory particle (RP). Structurally, the energy barrier created by Oprozomib triggers a long-range allosteric regulation, resulting in the stabilization of a non-productive state. Thereby, the chemical drug-binding signal is converted, propagated and amplified into structural changes over a distance of more than 150 Å from the proteolytic site to the ubiquitin receptor Rpn10. The direct visualization of changes in conformational dynamics upon drug binding allows new ways to screen and develop future allosteric proteasome inhibitors.
PubMed: 28541292
DOI: 10.1038/ncomms15578
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.8 Å)
Structure validation

235666

PDB entries from 2025-05-07

PDB statisticsPDBj update infoContact PDBjnumon